Business Wire

Forbes Travel Guide Announces New Leadership Structure to Support Expansion Plans to 100 Countries in 2019

Del

Forbes Travel Guide, the global authority on luxury travel, announced today a plan to significantly scale the company from evaluating and verifying luxury hospitality in 60 countries to 100 countries by the end of 2019. As part of this growth strategy, the company has made several key appointments and executive promotions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180724005232/en/

Filip Boyen, CEO of Forbes Travel Guide (Photo: Business Wire)

Filip Boyen, CEO of Forbes Travel Guide (Photo: Business Wire)

Gerard “Jerry” Inzerillo, who has served as CEO of Forbes Travel Guide since 2014, will be appointed Vice-Chairman of the Forbes Travel Guide Board of Directors and veteran luxury hospitality leader of 30 years, Filip Boyen, will be appointed CEO of Forbes Travel Guide. Filip was most recently the CEO of Small Luxury Hotels of the World, which he joined in 2015 following decades of stewardship with Orient Express Hotels and Resorts where his last role was Chief Operation Officer at Belmond and will remain in London.

“Jerry’s leadership and vision was a driving force in the company’s successful growth during these last four years,” said Jeff Arnold, Chairman of the Forbes Travel Guide Board of Directors. “We are delighted he will remain on the BOD and help guide our governance and strategic direction in this exciting new era of expansion. We wish him the very best in his new appointment from HRH, The Crown Prince of the Kingdom of Saudi Arabia Mohammed Bin Salman, as CEO of the Diriyah Gate Development Authority."

Arnold continued, “We are very excited to welcome Filip to the company as CEO with his valuable operational and revenue-growth expertise focusing on the development of new and expanded opportunities for our business. His extensive experience in luxury hospitality, commitment to guest service and proven track record as a global operator of luxury brands will help us to continue our growth while remaining true to our commitment of unbiased excellence at this dynamic time of globalization in the luxury market.”

“It is a great honor for me to join the originators of the Five-Star hospitality rating system and to have the chance to work with such an exceptional group of professionals as we expand our services to the industry and our guests globally,” said Boyen.

The company also announced that Tony Hounshell will join the company as Executive Vice President of Finance and will be responsible for the global operations of the company’s finance and accounting divisions. Tony brings almost twenty years of senior financial services experience with leading firms including most recently, Ernst & Young. Additionally, veteran Forbes Travel Guide executives Peter Kressaty, Tom Flournoy, Amanda Frasier, Mica Hill and Marilyn Karstaedt have been promoted to Executive Vice Presidents.

ABOUT FORBES TRAVEL GUIDE

Forbes Travel Guide is the only independent, global rating system for luxury hotels, restaurants and spas. Started as Mobil Travel Guide in 1958, the company created the first Five-Star rating system in the United States. Today, Forbes Travel Guide’s incognito inspectors travel the world, evaluating properties based on up to 900 rigorous, objective standards. The company’s annual Star Ratings, reviews and daily travel stories help discerning travelers select the world’s best luxury experiences. For more information about Forbes Travel Guide, visit www.forbestravelguide.com.

Connect with Forbes Travel Guide:

Instagram: www.instagram.com/ForbesTravelGuide
Twitter: www.twitter.com/ForbesInspector
Facebook: www.facebook.com/ForbesTravelGuide

Contact information

Contact for Press Inquiries:
Jaret Keller
Key Group Worldwide
Email: jkeller@keygroup.tv
Work: 212.988.7701
Mobile: 917.628.0480

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 09:30Pressemelding

Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.